Clone:
REAL106
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IHC, IF
Alternative names:
B4, CVID3, Leu-12

Extended validation for CD19 Antibody, anti-human,
REAlease
®

Specificity

Knockout validation
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
WT
KO
View details
Fluorescence microscopy image of CD19 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD19-PE (REAL106, red) and counterstained with DRAQ5 (blue) as DNA stain.
View details
Fluorescence microscopy image of CD19 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD19-PE (REAL106, red) and counterstained with DRAQ5 (blue) as DNA stain.
Fluorescence microscopy image of CD19 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD19-PE (REAL106, red) and counterstained with DRAQ5 (blue) as DNA stain.
View details
Overlay histogram showing flow cytometric analysis of CD19 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD19-PE, clone (REAL106). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Overlay histogram showing flow cytometric analysis of CD19 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD19-PE, clone (REAL106). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD19 Antibody, anti-human,
REAlease
®

Overview

Clone REAL106 is an antibody fragment derived from the full CD19 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL106 recognizes the human CD19 antigen, a type I transmembrane glycoprotein of 95 kDa that belongs to the immunglobulin superfamily. CD19 is expressed on B cells throughout most stages of B cell differentiation, though its expression is down-regulated during their terminal differentiation to plasma cells. Expression of CD19 is also found in the majority of B cell–derived malignancies. CD19 is further present on follicular dendritic cells. On B cells, CD19 associates with CD21, CD81, and CD225 (Leu-13) forming a signal transduction complex.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

B4, CVID3, Leu-12

Detailed product information

Technical specifications

CloneREAL106
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD19
Alternative names of antigenB4, CVID3, Leu-12
Distribution of antigenB cells, dendritic cells
RRIDAB_2751067, AB_2751457, AB_2751445, AB_2751098, AB_2751079, AB_2784033, AB_2784034, AB_2784032, AB_2751091

References for CD19 Antibody, anti-human,
REAlease
®

Publications

  1. Nadler, L. M. et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 131(1): 244-250
  2. Fujimoto, M. et al. (2000) CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol. Res. 22(2-3): 281-298
  3. Poe, J. C. et al. (2001) CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int. Rev. Immunol. 20(6): 739-762
  4. Tedder, T. F. et al. (2002) CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with B-lymphocyte intracellular calcium responses. Biochem. Soc. Trans. 30(4): 807-811

Related products for
CD19 Antibody, anti-human,
REAlease
®

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?